Update on HER-2 as a target for cancer therapy: Herceptin in the clinical setting

@article{Miles2001UpdateOH,
  title={Update on HER-2 as a target for cancer therapy: Herceptin in the clinical setting},
  author={David W. Miles},
  journal={Breast Cancer Research},
  year={2001},
  volume={3},
  pages={380 - 384}
}
Herceptin is the first therapy for breast cancer which targets an oncogene product. This humanized antibody to HER-2 has been shown to have activity as a single agent in a phase II trial of heavily pre-treated patients with advanced breast cancer and, in phase III studies, its use with chemotherapy is associated with higher response rates, longer time to progression and improved survival when compared with chemotherapy alone. Retrospective analysis of data from these pivotal trials suggests… CONTINUE READING

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 11 references

First-line, nonhormonal, treatment of women with HER2 overexpressing metastatic breast cancer with herceptin (trastuzumab, humanised anti-HER2 antibody) [abstract 275

  • C Vogel, M Cobleigh, +7 authors S Shak
  • Proc Am Soc Clin Oncol 2001,
  • 2001
2 Excerpts

Pharmacokinetics (PK) and safety of tastuzumab (Herceptin®) when administered every three weeks to women with metastatic breast cancer [abstract 271

  • K Gelmon, A Arnold, S Verma, J Ayoub, F Hemmings, B LeylandJones
  • Proc Am Soc Clin Oncol 2001,
  • 2001
1 Excerpt

The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridisation (FISH) in the herceptin pivotal trials [abstract 291

  • RD Mass, C Sanders, K Charlene, L Johnson, T Everett, S Anderson
  • Proc Am Soc Clin Oncol 2001,
  • 2001
2 Excerpts

Similar Papers

Loading similar papers…